From rising AI investment to real enterprise impact in pharma and MedTech

AI investment is accelerating across life sciences, but value is not.

Most organisations are still trapped in pilots and isolated use cases, creating more complexity without meaningful competitive advantage. These initiatives remain fragmented and difficult to scale across the enterprise.

At the same time, the industry is facing a perfect storm:

  • Patent cliffs
  • Pricing pressure
  • Rising evidence generation and compliance costs
  • Increasing regulatory demands

This point of view explains why this gap exists, and what to do about it.

The answer is not more AI, but a different operating model. One built on agentic AI, redesigned end‑to‑end workflows, and a unified data and semantic foundation.

The goal is simple: free human expertise from repetitive cognitive work so it can focus where it matters most, on scientific judgment, decision‑making, and innovation.

Download the point of view

Learn how life sciences leaders are re‑architecting AI, data, and workflows to move from experimentation to scalable, enterprise‑wide impact.